Electrical Asymmetrical Flow Field-Flow Fractionation Analysis of the NIST Monoclonal Antibody Reference Material 8671

General Information

ID0047

Application Technology	Pharmaceutical, Protein, Antibody EAF4-UV-MALS
Info	Postnova EAF2000, PN3211 UV-Vis, PN3621 MALS
Keywords	Electrical Asymmetrical Flow Field-Flow Fractionation, National Institute of Standards and Technology,
-	Multi Angle Light Scattering, Monoclonal Antibody, Size Exclusion Chromatography, Aggregate
	Measurement, Aggregate Recovery

Introduction

The U.S. National Institute of Standards and Technology (NIST) has produced a reference material monoclonal antibody (RM 8671 NIST mAb), intended for use in evaluating the performance of methods for determining physicochemical and biophysical attributes of mAbs [1]. It provides a representative test molecule for development of novel technology for therapeutic protein characterization. The NIST mAb is intended for a variety of uses that may include system suitability tests, establishing method or instrument performance and variability, comparing changing analytical test methods, and assisting in method qualification. In this work, the NIST mAb is used to compare separation, aggregation, quantification, and recovery parameters for Asymmetrical Flow Field-Flow Fractionation (AF4) versus Size Exclusion Chromatography (SEC), and to demonstrate the capabilities of the new Electrical Asymmetrical Flow Field-Flow Fractionation (EAF4) module (Figure 1) to simultaneously measure size and surface charge characteristics of antibodies and proteins.




Figure 1: Schematic of EAF4 channel. In addition to hydrodynamic size separation via the flow field, an electric field allows for further separation by a molecule or particle's surface charge.



info@postnova.com www.postnova.com Postnova Analytics GmbH 86899 Landsberg, GERMANY T: +49 8191 985 688 0 Postnova Analytics UK Ltd. Worcestershire, WR14 3SZ, UK T: +44 1684 585167 Postnova Analytics Inc. Salt Lake City, UT 84102, USA T: +1 801 521 2004 Postnova Northern Europe 01630 Vantaa, FINLAND T: +358 9 8545 510

Experimental Details and Results

The NIST mAb was analyzed by SEC-UV-MALS (Figure 2) and AF4-UV-MALS to evaluate separation of monomer from aggregates and recovery by both techniques. The SEC columns used were Waters Ultrahydrogel 1000 and Ultrahydrogel 120 in series. Both analyses were performed using 1x phosphate buffered saline (PBS) as a mobile phase. Aggregates were not separated by SEC-MALS, but instead eluted with monomer in a single peak (Figure 2). Aggregates measured by AF4 (Figure 3) represented 10 % of the total mass injected as measured by UV-Vis (data not shown).




Figure 2: SEC-MALS analysis of NIST mAb.

Figure 3: AF4-MALS analysis of NIST mAb.

The NIST mAb was analyzed with EAF4-UV-MALS in 1x phosphate buffered saline (PBS) using a control run (no electric field) and two varied electric field strengths (Figure 4). The retention time shifted toward earlier elution with greater negative charge on the channel bottom, indicating the NIST mAb is negatively charged in 1x PBS. The shift in retention time can be related to the net drift velocity and plotted versus the applied electric field; the slope represents the electrophoretic mobility, which was measured to be -1.68 \pm 0.05 μ m cm V⁻¹ s⁻¹ under the experimental conditions in this study (Figure 5).




Figure 4: NIST mAb retention time shift with applied electric field.



Conclusion

The Electrical Asymmetrical Flow Field-Flow Fractionation system allows both size and surface charge separation, enabling measurement of size or molecular weight distribution and electrophoretic mobility. The open channel design of FFF allows for better recovery of injected mass than SEC. This is important for quantifying protein/antibody aggregates present in small relative amounts, and represents an advantage of FFF over SEC for aggregate quantification.

References

[1] www.nist.gov/news-events/news/2016/07/extraordinary-standard-new-nist-protein-could-spur-biopharmaceutical



info@postnova.com www.postnova.com Postnova Analytics GmbH 86899 Landsberg, GERMANY T: +49 8191 985 688 0 Postnova Analytics UK Ltd. Worcestershire, WR14 3SZ, UK T: +44 1684 585167 Postnova Analytics Inc. Salt Lake City, UT 84102, USA T: +1 801 521 2004 Postnova Northern Europe 01630 Vantaa, FINLAND T: +358 9 8545 510